Aditya Sood, MD1, Saad Ahmed, MD2, Lilly Hou, MD2, Jervon Wright, MD2, Charles Marvil, MD3, Ashish Samaddar, MD2, Anish Sangari, MD4, Justin Lin, MD2, Ethan Berman, MD2, Nitish Sood, MD5 1Northwell Health-NSLIJ, Manhasset, NY; 2North Shore University Hospital/Zucker School of Medicine at Hofstra University, New York, NY; 3Yale Digestive Diseases, New Haven, CT; 4Emory University School of Medicine, Atlanta, GA; 5University of Oklahoma College of Medicine, Oklahoma City, OK
Introduction: The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on pancreatic health has been a subject of significant medical research. Previous studies have investigated the link between these medications and different types of tumors, revealing that while there is no overall increase in tumor cases, a specific association with pancreatic cancer has been observed. Given the mixed findings and the critical nature of pancreatic cancer prognosis, GLP1 agonists may offer a therapeutic benefit that warrants investigation.
Methods: We utilized a retrospective cohort design and gathered data from the TriNetX database to investigate the impact of GLP-1 receptor agonists on pancreatic cancer outcomes. We established two cohorts based on GLP-1 receptor agonist exposure: Cohort 1 comprises patients diagnosed with malignant neoplasm of the pancreas who had not used GLP-1 analogues (prematch n= 157,809), and Cohort 2 comprises patients diagnosed with malignant neoplasm of the pancreas with concurrent use of GLP-1 analogues (prematch n= 3,247). We employed propensity score matching to align the cohorts based on age, race, gender, and medical history (postmatch n=3,243). We assessed the primary outcomes of mortality and CA-19-9 levels using over a five-year follow-up period. Large language models were used as proofreading aids in drafting this abstract.
Results: We observed significant differences in mortality and CA-19-9 levels between the cohorts. Specifically, mortality was lower in patients using GLP-1 receptor agonists (Cohort 2) at 32.5%, compared to 45.9% in those without GLP-1 (Cohort 1), with a risk difference of 13.4% (CI: 0.110, 0.158, p < 0.001). CA-19-9 levels were notably lower in GLP-1 users, with a significant reduction in risk (CI: 0.021, 0.062, p < 0.001).
Discussion: Our results exhibited a significant reduction in mortality rates among patients using GLP-1 receptor agonists, with the medication serving as a potential protective effect in improving survival outcomes in pancreatic care patients. Second, lower CA-19-9 levels were noted in patients treated with GLP-1 receptor agonists. This suggests that these drugs may influence tumor markers or modify tumor behavior, potentially indicating a change in the disease's progression or response to treatment. These findings emphasize the need for a nuanced approach when considering GLP-1 receptor agonists in the therapeutic regimen of pancreatic cancer.
Disclosures:
Aditya Sood indicated no relevant financial relationships.
Saad Ahmed indicated no relevant financial relationships.
Lilly Hou indicated no relevant financial relationships.
Jervon Wright indicated no relevant financial relationships.
Charles Marvil indicated no relevant financial relationships.
Ashish Samaddar indicated no relevant financial relationships.
Anish Sangari indicated no relevant financial relationships.
Justin Lin indicated no relevant financial relationships.
Ethan Berman indicated no relevant financial relationships.
Nitish Sood indicated no relevant financial relationships.
Aditya Sood, MD1, Saad Ahmed, MD2, Lilly Hou, MD2, Jervon Wright, MD2, Charles Marvil, MD3, Ashish Samaddar, MD2, Anish Sangari, MD4, Justin Lin, MD2, Ethan Berman, MD2, Nitish Sood, MD5. P0027 - Therapeutic Advantages of GLP-1 Receptor Agonists: Survival and Insights from Large Retrospective Pancreatic Cancer Cohorts, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
